Two Weeks' Notice from Allogeneic Sources.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 29941482.
- Also identified by DOI 10.1158/1078-0432.CCR-18-1552.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A novel pipeline for neoantigen-specific T-cell receptor (TCR) identification has been validated in ovarian cancer, making use of HLA-matched allogeneic healthy donor T cells. This workflow allows for the identification of tumor-specific TCRs 2 weeks after antigen-specific stimulation and eliminates problematic patient-to-patient variation in the selection of neoantigen-specific TCRs. <i>Clin Cancer Res; 24(21); 5195-7. ©2018 AACR</i> <i>See related article by Matsuda et al., p. 5357</i>.
Medical subject headings
- Hematopoietic Stem Cell Transplantation
- Ovarian Neoplasms